CMML
A drug approval specific to CMML would catalyze a surge of interest in the hematology-oncology community.
ASTX727 is an oral fixed-dose combination of HMA decitabine and cytidine deaminase inhibitor cedazuridine...
Patients with CMML who received an allogeneic HSCT earlier in the course of their disease had better outcomes.
Advertisement
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.